Australia's most trusted
source of pharma news
Posted 14 November 2025 AM
Johnson & Johnson’s Darzalex is the first new type of medicine in 12 years to be listed on the PBS for newly diagnosed Australians with multiple myeloma, a cancer that affects plasma cells in bone marrow.
Approved uses of this first-of-its-kind, targeted immunotherapy have been expanded and it is now reimbursed as a frontline treatment for Australians diagnosed with multiple myeloma who are not eligible for stem cell transplantation. It will be used in combination with lenalidomide and dexamethasone (DRd).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.